Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.45 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.45 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27099036 | 0.84 | CRBN (0.58) | CRBNIKZF3CSNK1A1GSPT1MAP1LC3B | |
| SCHEMBL30066522 | 0.84 | CRBN (0.60) | CRBNIKZF3CSNK1A1MAP1LC3BIKZF2 | |
| SCHEMBL29440022 | 0.82 | CRBN (0.58) | CRBNCSNK1A1GSPT1MAP1LC3B | |
| SCHEMBL22512119 | 0.82 | CRBN (0.58) | CRBNCSNK1A1GSPT1MAP1LC3B | |
| SCHEMBL22307191 | 0.81 | CRBN (0.61) | CRBNIKZF3CSNK1A1GSPT1MAP1LC3B | |
| SCHEMBL31722330 | 0.80 | CRBN (0.60) | CRBNIKZF3CSNK1A1GSPT1IKZF2 | |
| SCHEMBL29094767 | 0.80 | CRBN (0.62) | CRBN | |
| SCHEMBL27290606 | 0.79 | CRBN (0.59) | CRBNIKZF3CSNK1A1GSPT1MAP1LC3B | |
| SCHEMBL26739443 | 0.79 | CRBN (0.55) | CRBNIKZF3CSNK1A1GSPT1MAP1LC3B | |
| SCHEMBL21759455 | 0.79 | CRBN (0.67) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143195-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3924350-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020167518-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020167518-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143195-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | CRBN 121/4885IKZF3 218/4885CSNK1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.